Medications for Liver Carcinoma

10 results

  • avastin - bevacizumab injection, solution

    (Bevacizumab)
    Genentech, Inc.
    Avastin (bevacizumab) is a VEGF inhibitor used with chemotherapy to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, ovarian/fallopian tube/peritoneal cancer, and hepatocellular carcinoma. Also indicated for recurrent glioblastoma in adults.
    Medication Details
    Drug Interactions

  • cabometyx - cabozantinib tablet

    (Cabozantinib)
    Exelixis, Inc.
    Cabometyx treats advanced renal cell carcinoma (alone or with nivolumab), hepatocellular carcinoma after sorafenib, and locally advanced or metastatic differentiated thyroid cancer or neuroendocrine tumors (pancreatic and extra-pancreatic) in adults and patients 12 and older after prior therapy.
    Medication Details
    Drug Interactions

  • cyramza - ramucirumab solution

    (Ramucirumab)
    Eli Lilly And Company
    Cyramza (ramucirumab) treats advanced gastric, gastro-esophageal junction, non-small cell lung, colorectal, and hepatocellular cancers in adults, used alone or with chemotherapy after prior treatment failure or as first-line therapy for EGFR-mutant NSCLC.
    Medication Details
    Drug Interactions

  • imfinzi - durvalumab injection, solution

    (Durvalumab)
    Astrazeneca Pharmaceuticals Lp
    Imfinzi is a PD-L1 antibody indicated for adults with NSCLC (resectable, unresectable Stage III, or metastatic), limited- and extensive-stage SCLC, biliary tract cancer, unresectable hepatocellular carcinoma, dMMR endometrial cancer, muscle-invasive bladder cancer, and resectable gastric/GEJ adenocarcinoma. Administered as monotherapy or with chemotherapy.
    Medication Details
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    KEYTRUDA is a PD-1 blocking antibody that treats multiple cancers—including melanoma, lung, head and neck, bladder, colorectal, gastric, cervical, breast, and renal cancers—as well as MSI-H/dMMR and TMB-H solid tumors, used across neoadjuvant, adjuvant, and metastatic settings.
    Medication Details
    Drug Interactions

  • lenvima - lenvatinib capsule

    (Lenvatinib)
    Eisai Inc.
    LENVIMA treats adults with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) in pMMR or non-MSI-H patients who progressed after prior therapy.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions

  • stivarga - regorafenib tablet, film coated

    (Regorafenib)
    Bayer Healthcare Pharmaceuticals Inc.
    Stivarga treats adults with previously treated metastatic colorectal cancer, locally advanced or metastatic gastrointestinal stromal tumors (GIST) after imatinib and sunitinib, and hepatocellular carcinoma after sorafenib.
    Medication Details
    Drug Interactions

  • tecentriq - atezolizumab injection, solution

    (Atezolizumab)
    Genentech, Inc.
    Tecentriq is a PD-L1 blocking antibody indicated for non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and alveolar soft part sarcoma in adults and pediatric patients 2 years and older.
    Medication Details
    Drug Interactions

  • yervoy - ipilimumab injection

    (Ipilimumab)
    E.R. Squibb & Sons, L.L.C.
    Yervoy treats multiple advanced cancers in adults and pediatric patients (12+), including melanoma, renal cell carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma—primarily in combination with nivolumab.
    Medication Details
    Drug Interactions